參考價	￥ 1210

信號通路

MedChemExpress (M

CAS	1058137-23-7	純度	98.94%
分子量	443.49	分子式	C??H??N?O?
供貨周期	現(xiàn)貨	規(guī)格	10 mM * 1 mL
貨號	HY-15391	應用領域	醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥

Lucitanib (E-3810) 是 VEGFR 和 FGFR 的雙重抑制劑，有效和選擇性地抑制VEGFR1，VEGFR2，VEGFR3，F(xiàn)GFR1，F(xiàn)GFR2，IC50分別為7 nM，25 nM，10 nM，17.5 nM，82.5 nM。

詳細介紹

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務。

Lucitanib

CAS No. : 1058137-23-7

MCE 國際站：Lucitanib

產(chǎn)品活性：Lucitanib (E-3810) 是 VEGFR 和 FGFR 的雙重抑制劑，有效和選擇性地抑制VEGFR1，VEGFR2，VEGFR3，FGFR1，FGFR2，IC₅₀分別為7 nM，25 nM，10 nM，17.5 nM，82.5 nM。

研究領域：Protein Tyrosine Kinase/RTK

作用靶點：VEGFR | FGFR

In Vitro: Consistent with the inhibitory activity of VEGFR and FGFR auto-phosphorylation, Lucitanib potently inhibits VEGF and bFGF-stimulated HUVEC proliferation with IC₅₀ of 40 and 50 nM, respectively. Besides, Lucitanib (E-3810) also inhibits CSF-1R with IC₅₀ of 5 nM. Lucitanib potently inhibits FGFR2 activity (K_i<0.05 μM), follows by PDGFRα activity (K_i=0.11 μM). The K_i values obtained for DDR2, LYN, CARDIAK, CSBP (2), EPHA2, and YES range between 0.26 and 8 μM.

In Vivo: Lucitanib (E-3810), at oral dosing of 20 mg/kg for 7 consecutive days, completely inhibits (P<0.01) the bFGF induced angiogenic response compare with the response in vehicle-treated mice. Lucitanib (E-3810) shows a broad spectrum of activity, being active in all the xenografts tested (HT29 colon carcinoma, A2780 ovarian carcinoma, A498, SN12K1, and RXF393 renal carcinomas) with dose-dependent inhibition of tumor growth. E-3810 significantly delays growth during treatment, but tumors resume their growth when treatment is suspended; in a few cases, tumor regression is observed. The activity of Lucitanib (E-3810) given at the doses of 15 mg/kg is tested on MDA-MB-231 breast cancer transplanted subcutaneously, at a late stage, when tumor masses reach 350 to 400 mg. This tumor xenograft is very sensitive to Lucitanib (E-3810), with complete tumor stabilization lasting throughout the 30-day treatment. As in other tumor models, tumors re-grow after withdrawal of Lucitanib (E-3810) at a rate similar to control tumors.